Brief: Windtree Announces Issuance Of Istaroxime Patent For The United States For Acute Heart Failure
02/07/2025 14:05
July 2 (Reuters) - Windtree Therapeutics Inc WINT.O: WINDTREE ANNOUNCES ISSUANCE OF ISTAROXIME PATENT FOR THE UNITED STATES FOR ACUTE HEART FAILURE WINDTREE THERAPEUTICS INC - ISTAROXIME PATENT PROVIDES PROTECTION UNTIL 2039 WINDTREE THERAPEUTICS INC - ISTAROXIME APPROACHING PHASE 3 READINESS IN CARDIOGENIC SHOCK Source text: ID:nGNX296ZyY Further company coverage: WINT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Windtree Therapeutics
See all newsBrief: Windtree Therapeutics Announces It Has Signed A Letter Of Intent To Acquire Commloan
Brief: Windtree Therapeutics Announces It May Receive License Agreement Payments From Its Licensee For Renewed Acute Pulmonary Development By The Licensee
Brief: Windtree Therapeutics Stockholders Approve Key Proposals For Revenue And Profit Generation At The Special Stockholder Meeting
Brief: Windtree Therapeutics Terminates Seismic-C Clinical Study At 20 Enrollments - SEC Filing
Brief: Windtree Therapeutics Inc - Announces Interim Analysis Of Istaroxime Phase 2 Study